alosetron has been researched along with Adverse Drug Event in 3 studies
alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.
Excerpt | Relevance | Reference |
---|---|---|
" Gastroenterologists and their patients have been affected adversely by removal from the marketplace of two licensed agents for irritable bowel syndrome (IBS): alosetron and tegaserod." | 3.74 | Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care. ( Johnson, DA; Schiller, LR, 2008) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Liu, Z | 1 |
Shi, Q | 1 |
Ding, D | 1 |
Kelly, R | 1 |
Fang, H | 1 |
Tong, W | 1 |
Smith, DA | 1 |
Schmid, EF | 1 |
Schiller, LR | 1 |
Johnson, DA | 1 |
1 review available for alosetron and Adverse Drug Event
Article | Year |
---|---|
Drug withdrawals and the lessons within.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbolines; Colitis, Ischemic; Drug Design; Drug-R | 2006 |
2 other studies available for alosetron and Adverse Drug Event
Article | Year |
---|---|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care.
Topics: Adverse Drug Reaction Reporting Systems; Carbolines; Clinical Trials as Topic; Drug Approval; Drug L | 2008 |